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ABSTRACT
Background: High-dose pooled human immunoglobulin (PHIG) treatment is sometimes effective in superanti-
gen related inflammatory diseases, such as toxic shock syndrome and Kawasaki disease. Neutralizing anti-
body to superantigen might provide protection, but antigen independent immune regulation of PHIG is also a
proposed mechanism.
Methods: Staphylococcal enterotoxin B (SEB)-specific IgG antibody in PHIG products (Venoglobulin IH®) was
detected by ELISA. The suppressive effect of PHIG or its fragments on proliferation and cytokine (IL-4 and IFN-
γ) production from SEB-stimulated peripheral blood mononuclear cells was examined.
Results: SEB-specific IgG was detected in PHIG products. PHIG (6.25―25 mgml) suppressed SEB-induced
proliferation and cytokine production in a dose-dependent manner. Fab and F (ab’) 2 fractions of PHIG also
suppressed the responses, but depletion of SEB-specific antibody from PHIG did not affect the inhibitory ef-
fects. The Fc fragment of PHIG also showed partial, but significant suppression.
Conclusions: These data suggested the possibility that PHIG suppressed SEB-induced proliferation and cy-
tokine production by some mechanisms independent of the presence of neutralizing antibody.
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INTRODUCTION
Superantigens are exotoxins released from several
kinds of bacteria or viruses. They stimulate as much
as 10―20% of T lymphocytes bearing specific Vβ re-
gions of the T-cell receptor and contribute to many
kinds of inflammatory diseases, including toxic shock
syndromes,1 enterocolitis, neonatal toxic shock
syndrome-like exanthematous disease (NTED),2 and
possibly Kawasaki disease.3 Exposure to superanti-
gens produced by Staphylococcus aureus on skin le-
sions affects the severity of atopic dermatitis.4
Corticosteroid is widely used in the treatment of in-
flammatory diseases. However, corticosteroid does
not suppress superantigen-induced lymphocyte prolif-
erative responses.5 Resistance to superantigen-
induced T cell responses may be due to inactivation
of glucocorticoid receptors or modification of the T
cell receptor signaling pathway, which leads to gluco-
corticosteroid receptor α phosphorylation and inhibi-
tion of the nuclear translocation of the receptor.6,7
Calcineurin inhibitors such as FK506 effectively in-
hibit superantigen-induced responses. However,
treatment of the superantigen-mediated diseases with
these inhibitors is still challenging.8
High-dose pooled human immunoglobulin (PHIG)
therapy was of therapeutic use in some of the su-
perantigen related diseases. Specific antibodies to su-
perantigens can be detected in the sera from healthy
donors or PHIG products.1 Toxic shock syndrome
toxin (TSST-1) specific IgG antibody in cord blood ap-
pears to protect babies from NTED,9 suggesting that
neutralizing antibodies against superantigen can be
protective.10 On the other hand, several reports have
suggested the mechanisms of PHIG therapy to be
free from the presence of neutralizing antibody.11
In this paper, we investigated the suppressive ef-
fects of PHIG on the SEB-induced lymphocyte activ-
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ity and aimed to reveal antigen-specific and non-
specific mechanisms of the suppressive effect.1
METHODS
MEASUREMENT OF SEB-SPECIFIC IgG ANTI-
BODY
SEB-specific IgG antibody was measured in PHIG
(Venoglobulin IHⓇ, Mitsubishi Pharma Corporation,
Osaka, Japan) using an enzyme-linked immunosorb-
ent assay (ELISA). Microtiter plates were coated for
24 hours with 5 μgml (0.5 μg per well) of SEB dis-
solved in coating buffer (BD Pharmingen, San Diego,
CA, USA). After blocking nonspecific reactivity with
2% human albumin (Mitsubishi Pharma), plates were
incubated with 100 μl of PHIG (50―0.0008 mgml)
for 2 hours. Alkaline phosphatase (ALP)-conjugated
anti-human IgG (Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, PA, USA) was incubated for 1
hour and developed with P-NPP (KPL, Inc. Gaithers-
burg, MD, USA). Bound IgG was detected by absor-
bance at 450 nm using a plate reader (BIO-RAD, To-
kyo, Japan).
CELL CULTURE
Peripheral blood mononuclear cells (PBMC) from
healthy adult donors were isolated by Ficoll-Hypaque
(Pharmacia Co. Uppsala, Sweden) gradient centrifu-
gation and suspended in RPMI 1640 (Sigma Chemi-
cal Co., St. Louis, MO, USA) containing 10% fetal bo-
vine serum (Life Technologies Limited, Auckland,
New Zealand), 100 Uml of penicillin G sodium
(Sigma Chemical Co.) and 100 Uml of streptomycin
(Sigma Chemical Co.). Cells (1×105 per well) were
plated in 96-well round-bottom culture plates (Becton
Dickinson and Company, Franklin Lakes, NJ, USA)
and stimulated with 100 ngml of SEB (Toxin Tech-
nology, Sarasota, FL, USA) or 10 μgml of concana-
valin A (ConA) (Sigma Chemical Co.).
Dexamethasone (10−10 to 10−6 moll, Sigma Chemi-
cal Co.), PHIG (6.25―25 mgml) or fractions of PHIG
were added at the beginning of the culture. Mixtures
of PHIG and human albumin at different ratios were
applied to the culture to avoid the effect of dilution of
the culture medium.
Cultures were incubated for 72 hours at 37℃ in a
humidified, 5% carbon dioxide-containing incubator.
To detect proliferative responses, [3H]-thymidine
(0.25 μCiwell, Amersham Pharmacia, Buckingham-
shire, UK) was added for the final 16 hours, and ra-
dioactivity was determined by liquid scintillation
counting (Beckman Coulter, Inc., Fullerton, CA,
USA).
CYTOKINE ELISA
Cytokine levels in the culture supernatant were deter-
mined by sandwich ELISA, using rat monoclonal anti-
bodies specific for human IFN-γ or human IL-4 (BD
OptEIA ELISA Set, BD Pharmingen) according to the
manufacturer’s protocol. Samples were diluted
×100 for assay of IFN-γ and the sensitivity was 300
pgml. They were undiluted for assay of IL-4, and the
sensitivity was 7.8 pgml.
DEPLETION OF SEB-SPECIFIC NEUTRALIZING
ANTIBODY FROM PHIG
To obtain PHIG lacking SEB-specific antibody, PHIG
was dialyzed in PBS and applied to an SEB-
conjugated affinity column. The affinity column con-
tained SEB coupled to sodium cyanobromide-
activated formyl-cellulofine beads.
The flow-through fractions were pooled and con-
centrated to a protein concentration of 50 mgml in
PBS, and designated “anti-SEB-depleted PHIG.”
Preparation of mock-treated PHIG followed the same
procedure but substituted a column containing the
same beads without SEB. Depletion of SEB-specific
antibody was examined using ELISA. Depletion of
SEB-specific antibody was, however, incomplete.
Compared with the native PHIG, 8-fold less SEB-
specific antibody was detected in the anti-SEB-
depleted PHIG.
PREPARATION OF PHIG FRAGMENTS
For further experiments, three fragments of IgG (Fc,
Fab, and F (ab’) 2) were prepared. Fab fragment is a
heterodimer of the variable (V) domain and part of
the constant (C) domain from heavy (VH, CH) and
light (VL, CL) chains of immunoglobulin. Fc fragment
is a homodimer of the Cγ1 and Cγ2 domains of IgG
heavy chain. Fab and Fc fragments of PHIG were ob-
tained by papain digestion. The digested fragments
were applied to a protein G column. Fab fragments
were obtained in the flow-through fractions, and Fc
fragments were eluted from the column.
F (ab’) 2 fragment is a covalently conjugated pair of
Fab fragments. To obtain F (ab’) 2 fragments, PHIG
was digested by pepsin and applied to a protein A col-
umn. The low-molecular weight contaminants were
removed by filtration (50,000 Da cutoff). The concen-
trations of each fraction were adjusted to obtain mo-
lar concentrations identical to those in the original
PHIG.
The specificity and purity of the Fab, Fc, and F
(ab’) 2 fragments were confirmed using SDS-
polyacrylamide gel electrophoresis in reducing and
non-reducing conditions, cellulose acetate electropho-
resis, and gel-filtration analysis. Commercially avail-
able Fab, Fc, and F (ab’) 2 fragments (Capell Labora-
tories, West Chester, PA, USA) were used as con-
trols.
RESULTS
SEB-SPECIFIC IGG ANTIBODY IN PHIG
SEB-specific IgG antibody was detected by ELISA in
PHIG (Fig. 1). Specificity of the ELISA was examined
by pre-incubating PHIG (50 μgml) with serial con-
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Fig. 1 Detection of SEB-specific IgG antibody in PHIG. 
SEB-specific IgG antibody was detected by ELISA. Al-
though relatively high background using PBS was seen, se-
rial dilution (50―0.0008 mg/ml) of PHIG resulted in 
concomitant decrease of OD titer, suggesting the specificity 
of the ELISA.
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Fig. 2 Specificity of the ELISA was confirmed using an in-
hibition ELISA. PHIG (50 μg/ml) was pre-incubated with se-
rial concentrations of SEB before ELISA detection. Dose-
dependent inhibition was observed, and SEB (10 μg/ml) 
completely blocked the detection.
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Fig. 3 Proliferation and cytokine production of PBMC stimulated with SEB and 
ConA. PBMC (1×105) from healthy adult donors were stimulated with SEB (100 
ng/ml) or ConA (10 μg/ml) for 3 days. Either stimulant induced identical prolifera-
tive responses, but SEB induced IFN-γ dominant cytokine synthesis. Statistical dif-
ference was calculated by the Mann-Whitney U test.
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centrations of SEB (1 ngml―10 μgml). Dose-
dependent inhibition was observed, and the ELISA
titer was completely abolished (reduced to the back-
ground level) by adding 10 μgml of SEB (Fig. 2).
PHIG SUPPRESSED SEB-INDUCED PROLIFERA-
TION AND CYTOKINE PRODUCTION
SEB (100 ngml) and ConA (10 μgml) induced simi-
lar levels of proliferative responses to PBMC from
healthy donors. But SEB induced significantly more
IFN-γ and less IL-4 compared with ConA stimulation
(Fig. 3). Dexamethasone did not suppress SEB-
induced proliferative responses (data not shown).
PHIG significantly and dose-dependently sup-
pressed SEB-induced proliferation, IFN-γ and IL-4
production. Almost complete suppression of IL-4 was
obtained at the lower concentration (6.25 mgml) of
PHIG, but proliferation and IFN-γ was also sup-
Kato K et al.
442 Allergology International Vol 56, No4, 2007 www.jsaweb.jp
Fig. 4 Suppression of SEB-induced proliferation and cytokine production by PHIG. PHIG suppressed 
SEB-induced proliferation and cytokine production in a dose-dependent manner (triangle). Anti-SEB-de-
pleted PHIG (circles) also showed significant suppressive efects. The suppression was not statisticaly 
diferent from that of mock-treated PHIG (squares) at any concentrations. ＊p＜0.05, ＊＊p＜0.01 com-
pared with the responses without PHIG by paired t-test. Data are expressed as mean ± SD of 3 inde-
pendent triplicate cultures.
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pressed completely at the highest concentration (25
mgml) (Fig. 4, native PHIG). However, PHIG did
not suppress the ConA-induced responses at all (data
not shown), suggesting the suppression was not due
to a toxic effect of PHIG.
EFFECT OF REMOVING SEB-SPECIFIC ANTI-
BODY FROM PHIG
The role of neutralizing antibody in the inhibition of
SEB-induced responses was examined using anti-
SEB-depleted PHIG. As is shown in Figure 4, anti-
SEB-depleted PHIG also showed a suppressive effect
as well as the native PHIG. In the lower concentration
(6.25 mgml), the suppression seemed to be less
than that of mock-treated PHIG, but the difference
was not statistically significant.
EFFECTS OF PHIG FRAGMENTS ON THE SEB-
INDUCED RESPONSES
Fc, Fab, and F (ab’) 2 fragments of PHIG were pre-
pared to reveal the mechanism of PHIG’s inhibitory
effect on SEB-induced responses(Fig. 5). Both Fab
and F (ab’) 2 fragments also inhibited proliferation
and cytokine production at the concentrations compa-
rable to those of native PHIG. Similar to the native
PHIG, complete suppression of IL-4 was observed at
low concentrations of Fab and F (ab)’ 2 fragments,
but IFN-γ was also suppressed completely at the high-
est concentration.
Fc fragment also suppressed SEB-induced prolif-
eration and cytokine production in a dose-dependent
manner. IL-4 production was significantly suppressed
at as low as 2 mgml of Fc fragment (corresponding
to 6.25 mgml of PHIG), but the suppression was not
complete at the highest concentration. Significant
suppression of IFN-γ production and proliferation was
also observed at 6 mgml (corresponding to 18.75
mgml of PHIG) or higher concentrations of Fc frac-
tion.
DISCUSSION
High-dose PHIG treatment has been reported to be
effective in superantigen-related inflammatory dis-
eases.1 Several reports, including the present paper,
have shown the presence of superantigen-specific an-
tibody in PHIG preparations. Superantigen-specific
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Fig. 5 Suppression of SEB-induced proliferation and cytokine production by PHIG fragments. Fab (dia-
monds) and F(ab’ )2 (squares) fragments suppressed the responses as efectively as native PHIG 
(triangles). Fc fragment (circles) also partialy and significantly suppressed IL-4, and less efectively, IFN-γ 
and proliferation. ＊p＜ 0.05, ＊＊p＜ 0.01 compared with the responses without PHIG by paired t-test. 
Data are expressed as mean ± SD of 3 independent triplicate cultures.
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neutralizing antibody may partially explain the
mechanism of high-dose PHIG therapy.1 The protec-
tive effect of maternal TSST-1 specific antibody in
NTED has also been suggested.9
However, several reports have suggested that the
effect of high-dose PHIG is not due to a neutralizing
activity alone. Takata11 reported that PHIG decreased
superantigen-induced IL-12 and IFN-γ production, but
the effect was independent of the neutralizing activity
of IgG. Aukrust12 reported that patients with primary
hypogammaglobulinemia showed elevated levels of
IL-1, and administration of PHIG down-regulated the
IL-1 cytokine network in vivo. Campbell13 also re-
ported that 6 mgml of PHIG inhibited proliferation
and IL-4 secretion but not IFN-γ secretion of SEB-
stimulated PBMC. The inhibition was unrelated to
the presence of anti-SEB IgG, because PHIG deple-
tion of SEB-IgG showed similar inhibition of prolifera-
tion and IL-4 secretion.
We have shown that PHIG suppressed proliferation
and cytokine production of SEB-stimulated PBMC
(Fig. 4). Consistent with Campbell’s report13, IL-4
production was susceptible to the suppression at the
low concentration of PHIG (6.25 mgml), but higher
concentrations (25 mgml) of PHIG almost com-
pletely suppressed IFN-γ production as well. The con-
centrations of PHIG used in the experiment were
comparable to serum IgG levels in healthy adults (5―
15 mgml) and levels after high-dose PHIG therapy
(20―30 mgml).
Removal of SEB-specific antibody from PHIG re-
sulted in a small, statistically insignificant decrease in
the suppressive effect at the low concentration (6.25
mgml). At the higher concentrations of anti-SEB-
depleted PHIG, level of suppression was similar to
that of native PHIG. Although depletion of SEB-
specific antibody was not complete (only 8-fold less
activity), it was concluded that the role of neutralizing
activity in the PHIG was limited.
For further analysis of the suppressive mecha-
nisms, we have examined the effects of Fab and Fc
fractions of IgG. Purified Fab and F (ab’) 2 fragments
of PHIG suppressed the responses as effectively as
native PHIG, and complete suppression was obtained
at the highest concentration. These findings might
suggest that these fragments, containing SEB-
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specific binding activity, directly blocked the binding
of SEB to T cell receptors or MHC Class II mole-
cules. But the role of SEB-specific antibody remains
unknown, because these fragments contain variable
regions of IgG antibodies to any other components,
or the role of trace amounts of contaminating factors
could not be ruled out.
Interestingly, high concentration of Fc fragment,
which is completely free from neutralizing activity,
partially but significantly suppressed IL-4 production
and, less markedly, proliferation and IFN-γ produc-
tion induced by SEB. Different susceptibility to the
suppression might suggest the presence of a specific
mechanism to regulate the response to superanti-
gens. Suppression by Fc fragment was not thought to
be due to direct inhibition of T cell function, because
PHIG did not suppress ConA-induced proliferation.
In several recent reports, FcγRIIb was shown to in-
duce signal inhibition to B cells or antigen presenting
cells (APC).14 Generally, the induction involves cross-
linking of FcγRIIb and other FcγRs, as well as FcεRI15
via antigen-antibody complex. Our findings might
suggest the possibility that binding of Fc components
to FcγRIIb itself partially induce inhibitory signals to
APC, apart from antigen-specific binding of the anti-
body. Further studies may be needed to reveal the
mechanism of regulation of immune systems by im-
munoglobulin itself. Highly purified or recombinant
immunoglobulin fragments might prove useful for
treatment or prophylaxis of superantigen-induced dis-
eases.
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